Study Finds Semaglutide Reduces Heavy Drinking in People With Obesity
In Brief
This research may influence future treatment options for alcohol-use disorder, especially among individuals with obesity.
Key Facts
- A clinical trial found semaglutide reduced alcohol consumption in people with obesity seeking treatment for alcohol-use disorder.
- The study is described as a 'gold standard' trial, indicating a high level of scientific rigor.
- Wegovy, a brand name for semaglutide, was associated with three positive effects on drinkers, according to The Independent.
- The study specifically examined individuals who were already seeking help for alcohol-use disorder.
- GLP-1 drugs like semaglutide are being researched for uses beyond weight loss, including potential impacts on alcohol consumption.
What Happened
A recent clinical trial found that semaglutide, a GLP-1 drug, reduced heavy drinking in people with obesity who were seeking treatment for alcohol-use disorder.
Why It Matters
These findings suggest that medications initially developed for weight loss may have broader applications in treating alcohol-use disorder, potentially expanding therapeutic options for affected individuals.
What's Next
Further research may be conducted to confirm these results and to explore the use of GLP-1 drugs for alcohol-use disorder in broader populations.
Sources
- MarketWatch — Can GLP-1s curb alcohol use? A new study says the drugs can reduce heavy drinking.(2h ago)
- The Independent — New study finds Wegovy shots have three positive effects on drinkers(39m ago)